Clinician

Translating research evidence into clinical practice often has a long lag time. To determine the impact of a phase III randomised controlled trial on palliative care clinicians’ self-reported practice change. Online survey about use of octreotide in managing inoperable malignant bowel obstruction due to cancer or its treatments distributed in November 2016, 2？years after the first publication of the study in a peer-reviewed journal. Demographic, self-reported practice and the reasons underpinning this were collected. Responses were aggregated to ‘practice modified’ or ‘practice not modified’. A multinomial regression model explored predictors of practice change. Members of the Australian New Zealand Society of Palliative Medicine. Response rate was 20.8% (106/509): 55.6% were aged >50？years, 56.5% were female and 77% had previously prescribed octreotide for this clinical indication. Out of 106 respondents, 52 (49.1%) indicated modified practice (60.9% of those who had previously prescribed octreotide in this setting). In those who reported practice change, most frequently octreotide was now used when other therapies failed; for not changing practice, ‘more confirmatory evidence was needed’ was most often cited. In the regression model, older age (clinician age？=？50–59？years; relative risk？=？0.147; 95% confidence interval？=？0.024–0.918; p？=？0.04) and having practices with lower proportions of people treated with octreotide (0%–20%; relative risk？=？0.039; 95% confidence interval？=？0.002–0.768; p？=？0.033) predicted greater self-reported practice change. Clinician-reported change in practice in the survey is seen in the majority of respondents. This suggests that there is a cohort of ‘early adopters’ within palliative care practice as new evidence becomes available